Novo Holdings A/S and Pfizer Inc. invest in TherAchon Holding AG

TherAchon Holding AG, a clinical-stage biotechnology company focused on rare diseases, has completed a USD 60 million mezzanine financing. The round was led by Novo Holdings A/S and joined by, inter alia, Pfizer Inc. and Cowen Healthcare Investments. TherAchon develops a novel protein therapy for achondroplasia, the most common form of short-limbed dwarfism.

The financing was successfully completed by the end of July 2018.

Lenz & Staehelin advised Novo Holdings A/S, Pfizer Inc. and four other new investors in this transaction.